Clinical Trial

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

Study acronym: Bvax
Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The objectives of this phase I first-in-human trial are to evaluate safety, feasibility, and preliminary efficacy of an individualized Bvax vaccine in addition to standard of care chemoradiation in patients with newly diagnosed glioblastoma.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2028-06-01 -> 2028-09-01 2026-06-03
minor Completion pushed: 2030-06-01 -> 2030-09-01 2026-06-03
Trial Details
NCT Number NCT07422896
Lead Sponsor Catalina Lee Chang
Conditions Glioblastoma
Enrollment 25 participants
Start Date 2026-09-01
Primary Completion 2028-09-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-02